Itraconazole, Serum or Plasma
Also known as: Sporanox®
Use
Treatment of susceptible fungal infections in immunocompromised and immunocompetent patients including blastomycosis and histoplasmosis; indicated for aspergillosis and onychomycosis of the toenail and fingernail. It has been recommended that routine monitoring occur during the first week of therapy to ensure therapeutic levels are achieved for each individual and to continue monitoring if clinical presentations do not improve or decline.
Special Instructions
Transfer separated serum or plasma to a plastic transport tube. Gel barrier tubes should not be used due to the potential for drug absorption by the gel, which can lead to clinically significant decreases in drug levels.
Limitations
This test has been developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. However, the FDA has determined that such clearance or approval is not necessary.
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 10989-2
- 18337-6
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube
Collection Instructions
Transfer separated serum or plasma to a plastic transport tube. Do not use a gel barrier tube.
Storage Instructions
Refrigerate. Stable for 14 days at room temperature, refrigerated, or frozen.
Causes for Rejection
Gel barrier tubes
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |